CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To understand and address, through clinical and translational research, the disease burden associated with localized prostate cancer in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to localized prostate cancer.
- To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/ international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to localized prostate cancer.

7:00 am  Welcome  A. Loblaw & N. Fleshner

Ongoing studies:

7:05 am  PR.15 Phase III Study of HDR Brachytherapy in Intermediate Risk CaP  E. Vigneault/ A. Loblaw

Study Proposal Update

7:10 am  ENZARAD (ANZUP - phase III radiation plus androgen deprivation with or without Enzalutamide for high risk, localized prostate cancer)  T. Niazi

continued on next page ...
**New Study Proposal/Ongoing studies**

7:30 am MAST trial N. Fleshner

7:35 am Time Combination of metformin with radical radiotherapy for localized prostate cancer. T. Tsakiridis

7:50 am New concept/proposals developments All

8:00 am Meeting Adjourned